Kimera Labs

Supplement

Experience the Kimera Difference

Services
  • Exosomes
Location Miramar, Florida
About

Kimera Labs

Kimera Labs is the leading exosome biotechnology laboratory specializing in the production of perinatal mesenchymal stem cell (MSC)-derived exosome products used for cosmetic and research purposes.

For over a decade, Kimera Labs has led the way in exosome biotechnology, setting the global standard for purity, consistency, and scientific excellence. From our FDA-inspected, GMP-certified, 27,000 sq. ft. laboratory in Miramar, Florida, we produce the industry’s most advanced mesenchymal stem cell (MSC)-derived exosome products, powered by our proprietary pre-COVID, single-donor placental MSC line.

Our product portfolio includes:

  • Luxir™ & Luxir+™ – Advanced cosmetic exosome formulations delivering trillions of microvesicles enriched with exosomes to support skin vitality, renewal, and radiance. Luxir provides a powerful foundation of over 5 trillion microvesicles, while Luxir+ amplifies results with an extraordinary 15 trillion, offering providers a spectrum of potency tailored to client needs.

  • Vive™ – The gold standard in hydration, formulated to optimize skin health and longevity through advanced exosome science.

  • Kiara™ – A revolutionary conditioned medium enriched with extracellular vesicles, growth factors, proteins, peptides, and amino acids.

At Kimera Labs, every product reflects our mission: to advance the science of exosomes with unmatched quality and innovation, empowering providers worldwide to achieve exceptional results.

Unlock exclusive discounts and offers from Kimera Labs and other trusted partners with an SSRP Pro Membership.
What People Say

Testimonials

After just one application of Luxir topically post-microneedling, the change in my skin was undeniable. It looked and felt healthier and more vibrant. Luxir is not only an important part of my skincare routine, but it is a vital component of my self-care regimen.

Network with our partners

Upcoming Events

View Upcoming Events
EVENT
Grand Rounds
December 4 - 5, 2026

Grand Rounds

Coming Soon
RESOURCES

Join us in breaking down the latest research live.

VIEW ALL
PODCAST
Redox Revolution
Sep 15, 2026
Ep.77 – Enhancing Orthopedic Outcomes and Improving Healing in Patients with Dr. Rahman
Ep.77 – Enhancing Orthopedic Outcomes and Improving Healing in Patients with Dr. Rahman

Dr. Seeds sits down with Omar Rahman, M.D. to talk about how peptide therapy can enhance orthopedic outcomes and speed up healing in patients.

Peptides & Protocols · Performance & Recovery
SSRP Institute Sep 14, 2026
In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD
HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]
READ NEWS
EVENT
Certification
September 10 - 11, 2027
Peptide Therapy Certification 2027
Four Seasons Resort Orlando at Walt Disney World, FL
COMING SOON
Certification
Peptide Therapy Certification 2027
COMING SOON
EVENT
World Congress
June 17 - 19, 2027
Peptide World Congress 2027
Arizona Biltmore, Phoenix, AZ
COMING SOON
World Congress
Peptide World Congress 2027
COMING SOON
EVENT
Mastermind
February 15 - 19, 2027
Fellowship Mastermind Summit 2027
Gansevoort Meatpacking NYC, New York, NY
COMING SOON
Mastermind
Fellowship Mastermind Summit 2027
COMING SOON
EVENT
Grand Rounds
December 4 - 5, 2026
Grand Rounds
Four Seasons Resort and Residences Vail
COMING SOON
Grand Rounds
Grand Rounds
COMING SOON
VIDEO
Cellular Medicine Mondays
Sep 14, 2026
Ep. 105 - Dr. Seeds’ Office Hours
Preview Only
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
HEADLINE SCIENCE [August 27, 2026] – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE [August 21, 2026] – JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the […]
READ NEWS
IntellxxDNA Aug 12, 2026
SSRP Institute Welcomes IntellxxDNA as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP’s mission to advance science-first, education-driven clinical collaboration. IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using […]
READ NEWS
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE